Online interest in calcitonin gene‐related peptide‐therapies: An infodemiology study using Google trends
Bradley Ong, Jad El Ahdab, Nicolas Thompson, Maithili Bhagat, John Ney, Allison L. Weathers · 2026
Read Online interest in calcitonin gene‐related peptide‐therapies: An infodemiology study using Google trends by Bradley Ong, Jad El Ahdab, Nicolas Thompson, Maithili Bhagat, John Ney, Allison L. Weathers (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13571050.txt.
Description
Bradley Ong and colleagues measured how product milestones moved public curiosity about migraine therapies that block CGRP, a pain-related peptide. These drugs transformed migraine care, but whether trial news, approvals, launches, or advertising actually drove awareness was unclear. Their infodemiology study tracked monthly Google Trends data from January 2017 to July 2025 for seven therapies in the United States, with a secondary look at one drug across five European countries.
Commercial launches produced immediate search jumps for erenumab and galcanezumab, while several other drugs gained steadily after launch; media exposure also spiked searches. Regulatory approvals and trial publications, by contrast, did not reliably move the needle. The authors conclude that launches and media, more than science or regulation alone, shape when patients start looking for a new migraine therapy.
Catalog record
| CREATOR | Bradley Ong, Jad El Ahdab, Nicolas Thompson, Maithili Bhagat, John Ney, Allison L. Weathers |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |